Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Blood Plasma
64%
Human Immunodeficiency Virus 1
62%
COVID-19
61%
Human Immunodeficiency Virus
53%
Omicron Coronavirus Variant
44%
Viral Load
43%
Antibody Response
37%
Epstein Barr Virus
29%
Viral Disease
27%
Neutralizing Antibody
24%
Virus Infectivity
23%
Vaccine Efficacy
21%
CD4 Lymphocyte Count
19%
Monospecific Antibody
17%
Hepatitis B Virus
17%
Immunocompromised Patient
17%
Titer
16%
Immune Response
15%
Spike
15%
Vaccination Policy
15%
Hepatitis C Virus
14%
T Cell
13%
Inflammatory Arthritis
13%
Cell Culture
12%
Immunosuppression
12%
Coinfection
11%
Cytokine
11%
BK Virus
11%
Real Time Polymerase Chain Reaction
11%
Seroprevalence
11%
Adaptive Immune System
11%
Human Immunodeficiency Virus Infection
10%
Neutralization
10%
Breakthrough Infection
10%
Virus
10%
Reverse Transcriptase
10%
Human Immunodeficiency Virus Type 1 Subtype C
10%
Peripheral Blood Mononuclear Cell
9%
Toxoplasmosis
8%
Seropositivity
8%
Metagenomic Next-Generation Sequencing
8%
Maturation
8%
Chemokine
8%
Human Cytomegalovirus
8%
Cerebrospinal Fluid
8%
Autoimmune Disease
8%
Macrophage Inflammatory Protein
8%
Human Herpesvirus 8
8%
JC Virus
8%
Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
67%
COVID-19
45%
Infected Individual
39%
South India
35%
India
29%
Antibody Response
26%
Nave
20%
Infectious Virus
18%
Hepatitis B Virus
17%
Pregnant Women
17%
Tertiary Care Hospital
17%
Unvaccinated
16%
Epstein-Barr Virus
16%
Convalescent Plasma
16%
Healthy Controls
15%
Antibody Level
14%
Variants of Concern
13%
Omicron Variant
13%
Immunocompromised Patients
13%
HIV Patients
12%
Immune Response
12%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
12%
Viral Kinetics
12%
Viral Load
12%
Hospitalization
12%
Co-infection
11%
EBNA1
11%
Viral
11%
HIV Viral Load
11%
Virus
11%
Plasma Viral Load
11%
Cell Culture
11%
SARS-CoV-2 Infection
10%
Genomic Surveillance
10%
Virus Diseases
10%
Drug-resistant Variant
10%
Antiretroviral Therapy
10%
Peripheral Blood Mononuclear Cells
9%
COVID-19 Vaccine
9%
CD4 Count
9%
Epstein-Barr Virus Infections
8%
PMTCT
8%
COVID-19 mRNA Vaccine
8%
Gastric Adenocarcinoma
8%
Combivir
8%
Uganda
8%
Healthy Individuals
8%
Antiretroviral Prophylaxis
8%
Neurotropic Virus
8%
Delta Variant
8%